Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.
Robert L. Ferris, MD, PhD
It is well accepted that for most cancers across settings, the use of combination therapies is the standard of care to maximize outcomes. Indeed, clinical trials evaluating conventional modalities such as chemotherapy with or without radiation in the definitive or postoperative adjuvant setting have focused on most efficacious combinations. Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.
Innovative developmental trial designs are necessary and results often get presented at disease-specific meetings like the recent 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers (GI) Symposium or the ASCO Genitourinary (GU) Cancers Symposium. The proliferation of trial acronyms that companies use to develop their trial portfolios (TOPAZ, HIMALAYA, CIRCULATE, etc.) reflects the many phase 2 and phase 3 clinical trials. These symposia focused on combinations of PD-1 inhibitors with radiation, chemotherapy, or targeted inhibitors in the preoperative neoadjuvant setting or postoperative setting for high-risk disease. Furthermore, findings were widely presented in locally advanced or recurrent, chemotherapy-refractory disease.
Overall, trials discussed at these 2 symposia, and detailed in this issue, have reported novel findings using various combinations of IO and small molecule inhibitors, showing that the promise of targeted immunotherapy and genomeguided oncology drugs is rich with new findings and trial designs.
Quite reassuringly, positive data are being seen in early-phase combinations, which bodes well for clinical outcomes in GU and GI cancers. Indeed, improvements in survival with add-on strategies—which are additive or synergistic—are needed to harness the power of greater biological understanding of disease, addressed through cancer immunotherapy and precision oncology.
I recommend reviewing the results of phase 2 and phase 3 randomized trials from the recent disease-specific GI and GU symposia, which are well reported in this issue. These trials contain a wealth of exciting findings and provide a paradigm across other cancers for integrating these novel biologically driven therapies with the conventional regimens and modalities we have used for years.
As we appear to be emerging from the pandemic, it is reassuring that scientific advancements and clinical investigation have kept up and are continuing the progress forward for our patients.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More